Although TNBC has a greater response rate to immune checkpoint inhibitors (ICIs) than other breast cancer subtypes, monotherapy response rates remain extremely low, with only 5% of unselected patients responding and 23% of PD-L1-positive patients responding (5, 6). This evidence concerns the gene CD274 and breast carcinoma.